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Malignant pleural effusions (MPEs) are a common 
diagnostic challenge for the respiratory physician. Their 
incidence is increasing with an estimated 150,000 new cases 
in the USA annually (1). As well as an increasing incidence, 
patients with MPE are presenting older due to ageing 
population and improved survival from primary cancer. 
The survival from diagnosis of all-cause MPEs is poor at 
around 5 months (2). Therefore, a clear and minimally 
invasive pathway for investigating these patients is essential. 
Currently, the mainstay of early investigation is computed 
tomography (CT) scanning and pleural fluid sampling for 
cytological analysis. 
Computed tomography is recommended on all patients 
with an undiagnosed unilateral exudative pleural effusion 
as a quick and non-invasive method of imaging the 
pleura (3). Various studies have assessed the sensitivity of 
CT for detecting malignant pleural disease. Hallifax et al. in 
2015 performed a retrospective review of 370 thoracoscopy 
procedures where the patient had a CT scan prior to the 
procedure (4). This analysis involved interpreting the 
radiologists reporting of the scan as to their certainty of 
malignancy. The sensitivity and specificity of CT was 
calculated using the thoracoscopic biopsy results as gold 
standard and was 68% and 78% respectively. Several further 
analyses have been performed and apart from a known 
false negative rate, especially for certain tumours (e.g., 
mesothelioma), the utility of CT scanning is unequivocal. 
Pleural fluid cytology is another cornerstone in the 
investigation of malignant pleural disease and again is 
recommended in all patients with undiagnosed unilateral 
pleural effusions. The sensitivity of cytology to detect 
malignant disease varies depending on the population 
studied and the immunohistochemical techniques used. 
A recent UK based prospective study found the overall 
sensitivity for detecting malignancy was 46% (95% CI, 42–
58%) with a considerable number of mesothelioma cases, in 
whom cytological yield was just 6% (5). When this analysis 
was limited to just lung carcinomas, sensitivity rose to 
56%, and higher still in lung adenocarcinomas (82%). The 
downsides of pleural fluid cytology include the time taken 
for immunohistochemical analysis, up to 5–7 days, during 
which the patient may be symptomatic without definitive 
management of their effusion. Additionally, it is still an 
invasive test and may not be immediately possible in those 
on anticoagulation or with only a small amount of pleural 
fluid. 
Positron emission tomography (PET) scanning is 
becoming increasingly used in malignant disease given 
improved availability and evidence base. It has been full 
incorporated in the diagnostic and treatment pathway of lung 
cancer but without a clear translation to MPE investigation 
currently. In MPE most studies have focused on the ability of 
PET to diagnose and stage mesothelioma (6,7). The drawback 
of PET in all-cause effusions suspicious of malignancy are 
the false positives due to other causes of pleural inflammation 
including inflammatory pleuritis, parapneumonic effusions 
or previous pleurodesis. Additionally, the availability of PET 
scanners varies dramatically worldwide so any guidelines 
should take this into account. 
A meta-analysis of diagnostic accuracy studies focusing 
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Arnold and Maskell. PET imaging for malignant effusions
specifically on PET for MPEs, was performed by Porcel 
et al. in 2015 (8). From 14 studies (comprising 407 patients 
with malignant disease) the pooled test characteristics of 
PET imaging had a sensitivity of 81% and specificity of 
74%. The studies included were highly heterogenous, and 
authors concluded that there was no basis for the routine 
inclusion of PET in the diagnosis of malignant pleural 
disease. Other roles for PET have been explored. The 
TARGET trial is currently under follow-up and explores 
the potential role of PET-CT to target areas of high uptake 
when performing a CT guided biopsy (9). 
The study published in this edition of JTD by Brun and 
colleagues assesses the correlation between CT scanning 
and pleural fluid cytology with PET (10). They focus on a 
cohort of 101 patients with proven MPEs secondary to lung 
cancer. Their analysis is retrospective across a 7-year period 
in a single centre French hospital. All patients had a CT and 
pleural fluid analysis, with a proportion also having a PET 
scan as part of their diagnostic work up. Their focus on a 
single primary site is important as often the study of MPEs 
is hampered by the inclusion of many different primary 
malignancies. 
The sensitivity of pleural fluid cytology amongst these 
patients was 60%, which is in keeping with previous 
literature for this condition. Interestingly, they also 
analysed the results from patients who had a repeat pleural 
fluid cytology sent at thoracoscopy. In those patients the 
cytological sensitivity was 67%. This adds value to previous 
literature that has recommended repeating the pleural 
fluid cytology (11). However, the authors of this editorial 
would caution against delaying thoracoscopy in patients 
where cytology is unlikely to give an answer e.g., males with 
previous asbestos exposure and no obvious primary tumour 
on baseline CT, or where tissue is likely to be required for 
targeted therapy (e.g., EGFR and ALK status). 
The analysis of the CT results, performed in all 101 
patients, showed that in 69 patients there was no clear 
evidence of malignancy (defined as pleural nodularity or 
thickening). A sensitivity of only 32% is lower than would 
be expected when compared to previous literature. The 
focus on lung cancers alone may have biased the study 
when compared to studies of all cause MPEs because a lung 
carcinoma can cause a reactive effusion without directly 
metastasizing to the pleura. Despite strict criteria for 
defining radiological malignancy (clear evidence of pleural 
nodules, masses and/or pleural thickening) CT evidence of 
malignancy did not translate into significantly worse overall 
survival in this cohort. 
This study did not find any value in PET imaging for 
diagnosis. Unfortunately, only a minority (47/101) patients 
had a PET performed as it was not standard of care (these 
were performed for staging purposes only). From these 
cases 68% had pleural enhancement indicating malignancy. 
This correlates with published literature. This study cannot 
give any estimates of specificity given the lack of a control 
group. Additionally, there was no correlation between PET 
findings, CT, pleural fluid cytology or survival. 
In terms of prognosticating patients with MPEs this 
paper has also not shown any role for PET. Patients with 
proven lung adenocarcinoma who present with a pleural 
effusion are automatically upstaged to “non-operability”. 
There is an argument that this is inappropriate given the 
lung cancer may not have caused the effusion by local 
invasion or metastasis into the pleura. Although there 
was a slight survival advantage in patients with no pleural 
changes on CT (2 months) or PET (2 months) these were 
not statistically significant. Previous literature has focused 
on the role of PET in prognosticating mesothelioma, 
where CT imaging is less helpful, but the evidence is not 
conclusive. Depending on the PET endpoint used some 
studies have shown a role in baseline prognostication 
but no ability to monitor disease (6). The recent BTS 
guidelines on mesothelioma do not recommend the routine 
use of PET-CT except in patients “where excluding 
distant metastases will  change management” (12). 
A potential future direction of study is the assessment of 
PET as a prognostic marker for lung cancer in patients 
with pleural effusions who might otherwise have been 
amenable for surgical resection. 
What this paper has shown is that there is no single or 
combination of non-invasive tests that can reliably diagnose 
MPEs. This condition continues to require a considered 
approach based on a thorough assessment of risk factors, 
CT imaging and thorough cytological testing. Even once 
these have been performed, there will continue to be a 
significant proportion of patients who will require biopsy 
(for tissue confirmation and genetic testing) or interval 
scanning in order to make a diagnosis. 
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